ABSTRACT

Understanding the mechanisms underlying the risk for infection in patients with hematological malignancies is the focus of considerable interest. Mechanisms underlying malignancy-related infections have been best studied in the more common disorders: chronic lymphocytic leukemia (CLL) and multiple myeloma (MM).1